Abstract: A method and medical preparation for enhancing tissue oxygenation by suppression of a hypoxia induced factor 1? (HIF-1?) in case of low oxygen tension in a tissue of a diabetic foot in a patient with type I or type II diabetes mellitus, wherein the method includes administering a dipeptide of L-glutamic acid-L-tryptophan (L-Glu-L-Trp), and wherein the medical preparation includes an effective amount of the dipeptide of L-Glu-L-Trp as an active agent and a pharmaceutically acceptable carrier. Moreover, the method can include administering the medical preparation in a dose of 1.0 ?g per kg-10.0 ?g per kg of body weight at least once a day for a period necessary to achieve a therapeutic effect.

Abstract: The present invention proposes a new use of dipeptide L-glutamic-L-tryptophan acid (L-Glu-L-Trp) for enhancing tissue oxygenation by suppression (reducing a synthesis) of HIF-1? factor in case of diabetic foot, a medical preparation including an effective amount of the dipeptide L-Glu-L-Trp as an active agent and a pharmaceutically acceptable carrier, and a method of treating a diabetic foot including locally administering the mentioned medical preparation comprising the dipeptide L-Glu-L-Trp in a dose of 1.0 ?g per kg-10.0 ?g per kg of body weight at least once a day for a period necessary to achieve a therapeutic effect. The technical result of invention includes providing a peptide preparation, which exerts an antihypoxic effect in diabetes mellitus of both types.

Abstract: Disclosed is a method of improving the conditioned reflex habit, the muscle tonus, or the motion coordination of a patient after suffering trauma to the brain cortex that involves administering to the patient an effective amount of a composition containing peptide glutamyl-aspartyl-arginine of the formula H-Glu-Asp-Arg-OH as its active base.

Abstract: Disclosed is a method of treating diseases. traumas. as well as consequences of traumas of the central nervous system. and a method for stimulating neurons regeneration. which involves the use of a peptide glutamyl-aspartyl-arginine. Also disclosed are a pharmaceutical composition containing the above peptide and a pharmaceutically acceptable carrier and a method of stimulating the regeneration of neurons by administering to a patient a pharmaceutical composition containing the above peptide in the dose of 0.01-100 ?g/kg of body weight at least once a day during a period necessary for attaining the therapeutic effect. such administration being performed parenterally.

Abstract: Disclosed is a peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1 [SEQ ID NO:1], having a stress protective effect. Also disclosed is a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier. Also disclosed is a method of preventing or treating functional or stress induced disorders in a patient wherein the method involves administering an effective amount of the peptide to the patient.

Abstract: Disclosed is a pharmaceutical composition for the prevention and correction of age-related disorders of cellular and humoral immunity and having an immunogeroprotective effect. The pharmaceutical composition includes a peptide glutamyl-aspartyl-proline with general formula H-Glu-Asp-Pro-OH sequence 1 [SEQ ID NO:1]. The pharmaceutical composition can be in the form suitable for parenteral administration. Also disclosed is a method of prevention and/or correction of age-related disorders of cellular and humoral immunity by stimulating the processes of lymphocytes proliferation and differentiation, such method consisting in the administration to a patient of a pharmaceutical composition containing an effective amount of peptide glutamyl-aspartyl-proline with general formula: H-Glu-Asp-Pro-OH sequence 1 [SEQ ID NO:1] in the dose of 0.01-100 ?g/kg of body weight as an active base at least once a day during a period necessary for attaining a therapeutic effect.

Abstract: The invention is related to the medicinal means of correction of metabolic vascular syndrome and diseases, associated with disordered vascular wall permeability and capillaries fragility, and can be used as a means of enhancing capillaries resistance. There is proposed a peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO:1], revealing biological activity and capable of enhancing capillaries resistance. There is also proposed a pharmaceutical composition enhancing capillaries resistance, containing effective amount of peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] as its active base and pharmaceutically acceptable carrier. This pharmaceutical composition is in form for parenteral administration.

Abstract: The invention refers to the pharmaceutical means for the treatment of cardiovascular diseases and can be used as a substance restoring myocardium function in the course of treatment for different forms of this pathology. There is proposed a new tetrapeptide alanyl-glutamyl-aspartyl-arginine with general formula: Ala-Glu-Asp-Arg sequence 1 [SEQ ID NO:1], revealing biological activity, which is manifested in the restoration of the myocardium function. There is proposed a pharmacological substance containing an effective amount of tetrapeptide alanyl-glutamyl-aspartyl-arginine with general formula: Ala-Glu-Asp-Arg sequence 1 [SEQ ID NO:1] as an active peptide agent, revealing biological activity, which is manifested by the restoration of myocardium function. Being included in the medication, this substance contributes to the restoration of the myocardium function.

Abstract: The invention refers to the medicinal remedies for respiratory system diseases treatment and may be applied as a substance, capable of restoring respiratory organs functions and used for treatment of different forms of lung pathology. There is proposed a biologically active new tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, capable of restoring respiratory organs function. There is proposed a pharmaceutical substance, containing as an active peptide agent an effective amount of tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, which if used in the medical preparation contributes to the restoration of the respiratory organs function.

Abstract: The invention is related to the medicinal means of prevention and correction of age-related disorders of cellular and humoral immunity and may be used as a medication revealing an immunogeroprotective effect. There is proposed a peptide glutamyl-aspartyl-proline with general formula H-Glu-Asp-Pro-OH sequence 1 [SEQ ID NO:1], revealing an immunogeroprotective effect. There is proposed a pharmaceutical composition revealing an immunogeroprotective effect containing an effective amount of peptide glutamyl-aspartyl-proline with general formula H-Glu-Asp-Pro-QH sequence 1 [SEQ ID NO:1] as its active base. In this case such pharmaceutical composition exists in the form suitable for parenteral administration.

Abstract: The invention is related to the medicinal means of treatment of diseases, traumas, as well as consequences of traumas of the central nervous system, and can be also used as a means of stimulating neurons regeneration. There is proposed a peptide glutamyl-aspartyl-arginine with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] capable of stimulating the regeneration of neurons. There is also proposed a pharmaceutical composition stimulating the regeneration of neurons containing peptide glutamyl-aspartyl-arginine with general formula H-GIu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] as its active base, as well as a pharmaceutically acceptable carrier. There is proposed a method of stimulating the regeneration of neurons consisting in the administration to a patient of the pharmaceutical composition, containing peptide glutamyl-aspartyl-arginine with general formula H-Glu-Asp-Arg-OH sequence 1 [SEQ ID NO:1] as its active base, in the dose of 0.

Abstract: The invention is related to the medicinal means of prevention and treatment for functional or stress induced disorders, which occur as a result of extreme impacts, and may be used as a medication revealing a stress protective effect. There is proposed a peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1 [SEQ ID NO:1], revealing a stress protective effect. There is proposed a pharmaceutical composition revealing a stress protective effect, characterized in that such composition contains an effective amount of peptide glutamyl-aspartyl-glycine with general formula H-Glu-Asp-Gly-OH sequence 1 [SEQ ID NO:1] as its active base, as well as a pharmaceutically acceptable carrier. In this case such pharmaceutical composition exists in the form suitable for parenteral or intranasal administration.

Abstract: The invention is related to the medicinal means of correction of metabolic vascular syndrome and diseases, associated with disordered vascular wall permeability and capillaries fragility, and can be used as a means of enhancing capillaries resistance. There is proposed a peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO:1], revealing biological activity and capable of enhancing capillaries resistance. There is also proposed a pharmaceutical composition enhancing capillaries resistance, containing effective amount of peptide lysyl-glutamyl-asparagine acid of the general formula H-Lys-Glu-Asp-OH sequence 1 [SEQ ID NO: 1] as its active base and pharmaceutically acceptable carrier. This pharmaceutical composition is in form for parenteral administration.

Abstract: The invention refers to the field of medicine and can be applied as a substance capable of regulating glucose level while treating and preventing diabetes mellitus. There is proposed a biologically active new tetrapeptide lysyl-glutamyl-aspartyl-tryp-tophane of general formula Lys-Glu-Asp-Trp-NH2 capable of regulating the glucose level, and pharmacological substance containing an effective amount of tetrapeptide lysyl-glutamyl-aspartyl-tryptophane of the general formula Lys-Glu-Asp-Trp-NH2. There is proposed the method of prevention and/or treatment of the diabetes mellitus, which consists in administering to a patient of the pharmacological substance, containing as an active peptide agent an effective amount of Lys-Glu-Asp-Trp-NH2 tetrapeptide in doses of 0.1-30 ?g/kg of the body weight at least once a day for a period necessary for attaining a therapeutic effect.

Abstract: The invention refers to the medicinal remedies for respiratory system diseases treatment and may be applied as a substance, capable of restoring respiratory organs functions and used for treatment of different forms of lung pathology. There is proposed a biologically active new tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, capable of restoring respiratory organs function. There is proposed a pharmaceutical substance, containing as an active peptide agent an effective amount of tetrapeptide alanyl-glutamyl-aspartyl-leucine of the general formula Ala-Glu-Asp-Leu, which if used in the medical preparation contributes to the restoration of the respiratory organs function.

Abstract: The invention refers to the pharmaceutical means for the treatment of cardiovascular diseases and can be used as a substance restoring myocardium function in the course of treatment for different forms of this pathology. There is proposed a new tetrapeptide alanyl-glutamyl-aspartyl-arginine with general formula: Ala-Glu-Asp-Arg sequence 1 [SEQ ID NO:1], revealing biological activity, which is manifested in the restoration of the myocardium function. There is proposed a pharmacological substance containing an effective amount of tetrapeptide alanyl-glutamyl-aspartyl-arginine with general formula: Ala-Glu-Asp-Arg sequence 1 [SEQ ID NO:1] as an active peptide agent, revealing biological activity, which is manifested by the restoration of myocardium function. Being included in the medication, this substance contributes to the restoration of the myocardium function.

Abstract: The invention refers to the field of medicine and may be applied as a substance stimulating the functional activity of hepatocytes, restoring the synthesis of non-specific proteins, normalising metabolism activating the processes of proliferation and differentiation of the liver cells. There is proposed a new compound -tetrapeptide lysyl-glutamyl-aspartyl-alanine of the general formula Lys-Glu-Asp-Ala [SEQ ID NO:1]. There is proposed a pharmaceutical composition capable of stimulating the functional activity of hepatocytes and a pharmaceutical peptide substance containing as its active base a therapeutically effective quantity of tetrapeptide of the formula Lys-Glu-Asp-Ala [SEQ ID NO:1] or one of its salts intended for parenteral administration. There is proposed a method of stimulating the functional activity of hepatocytes including therapeutic administration to a patient of the pharmaceutical peptide substance in doses 0.

Abstract: The invention refers to the field of medicine and may be applied as a substance stimulating the functional activity of hepatocytes, restoring the synthesis of non-specific proteins, normalising metabolism activating the processes of proliferation and differentiation of the liver cells. There is proposed a new compound—tetrapeptide lysyl-glutamyl-aspartyl-alanine of the general formula Lys-Glu-Asp-Ala [SEQ ID NO:1]. There is proposed a pharmaceutical composition capable of stimulating the functional activity of hepatocytes and a pharmaceutical peptide substance containing as its active base a therapeutically effective quantity of tetrapeptide of the formula Lys-Glu-Asp-Ala [SEQ ID NO:1] or one of its salts intended for parenteral administration. There is proposed a method of stimulating the functional activity of hepatocytes including therapeutic administration to a patient of the pharmaceutical peptide substance in doses 0.

Abstract: L-Lys-L-Glu dipeptide is proposed for use in medicine for preparation of a drug capable of stimulating repair processes. According to the invention, the pharmaceutical peptide preparation capable of stimulating regeneration consists of pharmaceutically admissible carrier and effective quantity of dipeptide as an active part, which is a combination of, L-lysil-L-glutamic acid or its salts. The pharmaceutical peptide preparation is proposed for parenteral, intranasal oral and local application. According to the invention, the method stimulating regeneration consists of prophylactic and/or treatment injections of the drug in the dose of 0.01-100 &mgr;kg per per 1 kg of weight, at least once a day during a period necessary for obtaining a therapeutic effect.

Abstract: Methods are provided for the therapy of immunodeficient, immunodepressed or hyperactive immune states and for the prevention and treatment of opportunistic infections in such states comprising administering to a subject a pharmaceutically acceptable composition comprising as an active ingredient the dipeptide L-Ile-L-Trp, linear and cyclic monomers and polymers thereof, and/or pharmaceutically acceptable salts thereof.